US 2024/0316209 A1Published application

Antibodies containing unnatural amino acids and methods of making and using the same

AssigneeBrickBio, Inc.

InventorsJames Sebastian Italia, Nikolaos Biris

Life of this patent

Estimating the term…

Abstract

The invention relates generally to engineered antibodies containing unnatural amino acids (UAAs) and methods of making and using such antibodies.

Claims62

Dependent claims

An antibody,

wherein the antibody comprises a heavy chain, or a fragment thereof, comprising:
(i) the amino acid sequence of SEQ ID NO:
118, with an unnatural amino acid (UAA) at a position corresponding to P6 of SEQ ID NO:
118;
the amino acid sequence of SEQ ID NO:
119, with an unnatural amino acid (UAA) at a position corresponding to P14 of SEQ ID NO:
119;
the amino acid sequence of SEQ ID NO:
120, with an unnatural amino acid (UAA) at a position corresponding to P14 of SEQ ID NO:
120;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to P14 of SEQ ID NO:
121;
(ii) the amino acid sequence of SEQ ID NO:
122, with an unnatural amino acid (UAA) at a position corresponding to G6 of SEQ ID NO:
122;
the amino acid sequence of SEQ ID NO:
123, with an unnatural amino acid (UAA) at a position corresponding to G17 of SEQ ID NO:
123;
the amino acid sequence of SEQ ID NO:
120, with an unnatural amino acid (UAA) at a position corresponding to G66 of SEQ ID NO:
120;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to G66 of SEQ ID NO:
121;
(iii) the amino acid sequence of SEQ ID NO:
124, with an unnatural amino acid (UAA) at a position corresponding to D6 of SEQ ID NO:
124;
the amino acid sequence of SEQ ID NO:
125, with an unnatural amino acid (UAA) at a position corresponding to D7 of SEQ ID NO:
125;
the amino acid sequence of SEQ ID NO:
120, with an unnatural amino acid (UAA) at a position corresponding to D73 of SEQ ID NO:
120;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to D73 of SEQ ID NO:
121;
(iv) the amino acid sequence of SEQ ID NO:
126, with an unnatural amino acid (UAA) at a position corresponding to L6 of SEQ ID NO:
126;
the amino acid sequence of SEQ ID NO:
127, with an unnatural amino acid (UAA) at a position corresponding to L6 of SEQ ID NO:
127;
the amino acid sequence of SEQ ID NO:
120, with an unnatural amino acid (UAA) at a position corresponding to L115 of SEQ ID NO:
120;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to L115 of SEQ ID NO:
121;
(v) the amino acid sequence of SEQ ID NO:
131, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
131;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to K3 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to K3 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to K124 of SEQ ID NO:
121;
(vi) the amino acid sequence of SEQ ID NO:
132, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
132;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to T18 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to T18 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to T138 of SEQ ID NO:
121;
(vii) the amino acid sequence of SEQ ID NO:
133, with an unnatural amino acid (UAA) at a position corresponding to A6 of SEQ ID NO:
133;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to A23 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to A23 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to A143 of SEQ ID NO:
121;
(viii) the amino acid sequence of SEQ ID NO:
134, with an unnatural amino acid (UAA) at a position corresponding to V6 of SEQ ID NO:
134;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to V37 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to V37 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to V157 of SEQ ID NO:
121;
(ix) the amino acid sequence of SEQ ID NO:
174, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
174;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to T38 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to T38 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to T158 of SEQ ID NO:
121;
(x) the amino acid sequence of SEQ ID NO:
135, with an unnatural amino acid (UAA) at a position corresponding to S6 of SEQ ID NO:
135;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to S40 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to S40 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to S160 of SEQ ID NO:
121;
(xi) the amino acid sequence of SEQ ID NO:
136, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
136;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to T47 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to T47 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to T167 of SEQ ID NO:
121;
(xii) the amino acid sequence of SEQ ID NO:
137, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
137;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to T78 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to T78 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to T198 of SEQ ID NO:
121;
(xiii) the amino acid sequence of SEQ ID NO:
138, with an unnatural amino acid (UAA) at a position corresponding to N6 of SEQ ID NO:
138;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to N84 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to N84 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to N204 of SEQ ID NO:
121;
(xiv) the amino acid sequence of SEQ ID NO:
139, with an unnatural amino acid (UAA) at a position corresponding to V6 of SEQ ID NO:
139;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to V85 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to V85 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to V205 of SEQ ID NO:
121;
(xv) the amino acid sequence of SEQ ID NO:
140, with an unnatural amino acid (UAA) at a position corresponding to N6 of SEQ ID NO:
140;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to N86 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to N86 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to N206 of SEQ ID NO:
121;
(xvi) the amino acid sequence of SEQ ID NO:
141, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
141;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to K93 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to K93 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to K213 of SEQ ID NO:
121;
(xvii) the amino acid sequence of SEQ ID NO:
142, with an unnatural amino acid (UAA) at a position corresponding to D6 of SEQ ID NO:
142;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to D95 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to D95 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to D215 of SEQ ID NO:
121;
(xviii) the amino acid sequence of SEQ ID NO:
143, with an unnatural amino acid (UAA) at a position corresponding to 16 of SEQ ID NO:
143;
the amino acid sequence of SEQ ID NO:
144, with an unnatural amino acid (UAA) at a position corresponding to 123 of SEQ ID NO:
144;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to 1136 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to 1256 of SEQ ID NO:
121;
(xix) the amino acid sequence of SEQ ID NO:
145, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
145;
the amino acid sequence of SEQ ID NO:
144, with an unnatural amino acid (UAA) at a position corresponding to K44 of SEQ ID NO:
144;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to K157 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to K277 of SEQ ID NO:
121;
(xx) the amino acid sequence of SEQ ID NO:
146, with an unnatural amino acid (UAA) at a position corresponding to Y6 of SEQ ID NO:
146;
the amino acid sequence of SEQ ID NO:
144, with an unnatural amino acid (UAA) at a position corresponding to Y48 of SEQ ID NO:
144;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to Y161 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to Y281 of SEQ ID NO:
121;
(xxi) the amino acid sequence of SEQ ID NO:
147, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
147;
the amino acid sequence of SEQ ID NO:
144, with an unnatural amino acid (UAA) at a position corresponding to K58 of SEQ ID NO:
144;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to K171 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to K291 of SEQ ID NO:
121;
(xxii) the amino acid sequence of SEQ ID NO:
148, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
148;
the amino acid sequence of SEQ ID NO:
144, with an unnatural amino acid (UAA) at a position corresponding to K60 of SEQ ID NO:
144;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to K173 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to K293 of SEQ ID NO:
121;
(xxiii) the amino acid sequence of SEQ ID NO:
149, with an unnatural amino acid (UAA) at a position corresponding to N6 of SEQ ID NO:
149;
the amino acid sequence of SEQ ID NO:
144, with an unnatural amino acid (UAA) at a position corresponding to N67 of SEQ ID NO:
144;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to N180 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to N300 of SEQ ID NO:
121;
(xxiv) the amino acid sequence of SEQ ID NO:
150, with an unnatural amino acid (UAA) at a position corresponding to F6 of SEQ ID NO:
150;
the amino acid sequence of SEQ ID NO:
151, with an unnatural amino acid (UAA) at a position corresponding to F64 of SEQ ID NO:
151;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to F287 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to F407 of SEQ ID NO:
121;
and/or
(xxv) the amino acid sequence of SEQ ID NO:
191, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
191;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to K16 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to K16 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to K136 of SEQ ID NO:
121;
and/or
wherein the antibody comprises a light chain, or a fragment thereof, comprising:
(i) the amino acid sequence of SEQ ID NO:
152, with an unnatural amino acid (UAA) at a position corresponding to V6 of SEQ ID NO:
152;
the amino acid sequence of SEQ ID NO:
153, with an unnatural amino acid (UAA) at a position corresponding to V15 of SEQ ID NO:
153;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to V15 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to V15 of SEQ ID NO:
155;
(ii) the amino acid sequence of SEQ ID NO:
156, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
156;
the amino acid sequence of SEQ ID NO:
153, with an unnatural amino acid (UAA) at a position corresponding to T20 of SEQ ID NO:
153;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to T20 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to T20 of SEQ ID NO:
155;
(iii) the amino acid sequence of SEQ ID NO:
157, with an unnatural amino acid (UAA) at a position corresponding to R6 of SEQ ID NO:
157;
the amino acid sequence of SEQ ID NO:
158, with an unnatural amino acid (UAA) at a position corresponding to R1 of SEQ ID NO:
158;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to R24 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to R24 of SEQ ID NO:
155;
(iv) the amino acid sequence of SEQ ID NO:
159, with an unnatural amino acid (UAA) at a position corresponding to S6 of SEQ ID NO:
159;
the amino acid sequence of SEQ ID NO:
160, with an unnatural amino acid (UAA) at a position corresponding to S4 of SEQ ID NO:
160;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to S60 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to S60 of SEQ ID NO:
155;
(v) the amino acid sequence of SEQ ID NO:
161, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
161;
the amino acid sequence of SEQ ID NO:
162, with an unnatural amino acid (UAA) at a position corresponding to K10 of SEQ ID NO:
162;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to K107 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to K107 of SEQ ID NO:
155;
(vi) the amino acid sequence of SEQ ID NO:
163, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
163;
the amino acid sequence of SEQ ID NO:
162, with an unnatural amino acid (UAA) at a position corresponding to T12 of SEQ ID NO:
162;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to T109 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to T109 of SEQ ID NO:
155;
(vii) the amino acid sequence of SEQ ID NO:
164, with an unnatural amino acid (UAA) at a position corresponding to V6 of SEQ ID NO:
164;
the amino acid sequence of SEQ ID NO:
162, with an unnatural amino acid (UAA) at a position corresponding to V13 of SEQ ID NO:
162;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to V110 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to V110 of SEQ ID NO:
155;
(viii) the amino acid sequence of SEQ ID NO:
165, with an unnatural amino acid (UAA) at a position corresponding to A6 of SEQ ID NO:
165;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to A1 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to A111 of SEQ ID NO:
155;
(ix) the amino acid sequence of SEQ ID NO:
167, with an unnatural amino acid (UAA) at a position corresponding to Q6 of SEQ ID NO:
167;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to Q37 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to Q147 of SEQ ID NO:
155;
(x) the amino acid sequence of SEQ ID NO:
168, with an unnatural amino acid (UAA) at a position corresponding to L6 of SEQ ID NO:
168;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to L44 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to L154 of SEQ ID NO:
155;
(xi) the amino acid sequence of SEQ ID NO:
169, with an unnatural amino acid (UAA) at a position corresponding to G6 of SEQ ID NO:
169;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to G47 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to G157 of SEQ ID NO:
155;
(xii) the amino acid sequence of SEQ ID NO:
175, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
175;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to K59 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to K169 of SEQ ID NO:
155;
(xiii) the amino acid sequence of SEQ ID NO:
170, with an unnatural amino acid (UAA) at a position corresponding to A6 of SEQ ID NO:
170;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to A83 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to A193 of SEQ ID NO:
155;
(xiv) the amino acid sequence of SEQ ID NO:
171, with an unnatural amino acid (UAA) at a position corresponding to V6 of SEQ ID NO:
171;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to V95 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to V205 of SEQ ID NO:
155;
(xv) the amino acid sequence of SEQ ID NO:
172, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
172;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to T96 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to T206 of SEQ ID NO:
155;
and/or
(xvi) the amino acid sequence of SEQ ID NO:
173, with an unnatural amino acid (UAA) at a position corresponding to S6 of SEQ ID NO:
173;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to $98 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to S208 of SEQ ID NO:
155.

467 more elements

A method of producing an antibody comprising an unnatural amino acid (UAA), the method comprising culturing a cell with:

(i) a nucleic acid comprising a nucleotide sequence encoding a tRNA comprising an anticodon that hybridizes to a codon selected from UAG, UGA, and UAA, and is capable of being charged with the unnatural amino acid (UAA);
(ii) a nucleic acid comprising a nucleotide sequence encoding an aminoacyl-tRNA synthetase capable of charging the tRNA with the unnatural amino acid (UAA);
and
(iii) a nucleic acid comprising a nucleotide sequence encoding a heavy chain, light chain or a combination of a heavy chain and light chain of the antibody and comprising the codon selected from UAG, UGA, and UAA;
under conditions that permit the tRNA, when expressed in the cell and charged with the unnatural amino acid (UAA), to hybridize to the codon and direct the incorporation of the unnatural amino acid (UAA) into the antibody;
wherein the antibody heavy chain, or a fragment thereof, comprises the amino acid sequence of SEQ ID NO:
128, with an unnatural amino acid (UAA) at a position corresponding to A6 of SEQ ID NO:
128;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to A1 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to A1 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to A121 of SEQ ID NO:
121;
and wherein
(a) the amount of the antibody comprising the unnatural amino acid (UAA) expressed by the cell is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the amount of a reference antibody expressed by the same cell or a similar cell, wherein the reference antibody is an otherwise identical antibody that does not comprise the UAA;
and/or
(b) following protein G purification, less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the antibody is aggregated, as measured by size exclusion chromatography (SEC).

18 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/044,943Filed 10 Sep 2021
Priority: 10 Sep 2020
Published: 26 Sep 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 47/6803
Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent: drugs conjugated to an antibody or…
A61K 47/68031
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being an auristatin
A61K 47/68033
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being a maytansine
A61K 47/6853
The antibody targeting a determinant of a tumour cell: carcino-embryonic antigens

Family

Application63/076,814Us provisional application · filed 10 Sep 2020
Application63/144,628Us provisional application · filed 2 Feb 2021
US 2024/0316209 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

The invention relates generally to engineered antibodies containing unnatural amino acids (UAAs) and methods of making and using such antibodies.

An antibody,

wherein the antibody comprises a heavy chain, or a fragment thereof, comprising:
(i) the amino acid sequence of SEQ ID NO:
118, with an unnatural amino acid (UAA) at a position corresponding to P6 of SEQ ID NO:
118;
the amino acid sequence of SEQ ID NO:
119, with an unnatural amino acid (UAA) at a position corresponding to P14 of SEQ ID NO:
119;
the amino acid sequence of SEQ ID NO:
120, with an unnatural amino acid (UAA) at a position corresponding to P14 of SEQ ID NO:
120;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to P14 of SEQ ID NO:
121;
(ii) the amino acid sequence of SEQ ID NO:
122, with an unnatural amino acid (UAA) at a position corresponding to G6 of SEQ ID NO:
122;
the amino acid sequence of SEQ ID NO:
123, with an unnatural amino acid (UAA) at a position corresponding to G17 of SEQ ID NO:
123;
the amino acid sequence of SEQ ID NO:
120, with an unnatural amino acid (UAA) at a position corresponding to G66 of SEQ ID NO:
120;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to G66 of SEQ ID NO:
121;
(iii) the amino acid sequence of SEQ ID NO:
124, with an unnatural amino acid (UAA) at a position corresponding to D6 of SEQ ID NO:
124;
the amino acid sequence of SEQ ID NO:
125, with an unnatural amino acid (UAA) at a position corresponding to D7 of SEQ ID NO:
125;
the amino acid sequence of SEQ ID NO:
120, with an unnatural amino acid (UAA) at a position corresponding to D73 of SEQ ID NO:
120;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to D73 of SEQ ID NO:
121;
(iv) the amino acid sequence of SEQ ID NO:
126, with an unnatural amino acid (UAA) at a position corresponding to L6 of SEQ ID NO:
126;
the amino acid sequence of SEQ ID NO:
127, with an unnatural amino acid (UAA) at a position corresponding to L6 of SEQ ID NO:
127;
the amino acid sequence of SEQ ID NO:
120, with an unnatural amino acid (UAA) at a position corresponding to L115 of SEQ ID NO:
120;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to L115 of SEQ ID NO:
121;
(v) the amino acid sequence of SEQ ID NO:
131, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
131;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to K3 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to K3 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to K124 of SEQ ID NO:
121;
(vi) the amino acid sequence of SEQ ID NO:
132, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
132;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to T18 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to T18 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to T138 of SEQ ID NO:
121;
(vii) the amino acid sequence of SEQ ID NO:
133, with an unnatural amino acid (UAA) at a position corresponding to A6 of SEQ ID NO:
133;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to A23 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to A23 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to A143 of SEQ ID NO:
121;
(viii) the amino acid sequence of SEQ ID NO:
134, with an unnatural amino acid (UAA) at a position corresponding to V6 of SEQ ID NO:
134;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to V37 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to V37 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to V157 of SEQ ID NO:
121;
(ix) the amino acid sequence of SEQ ID NO:
174, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
174;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to T38 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to T38 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to T158 of SEQ ID NO:
121;
(x) the amino acid sequence of SEQ ID NO:
135, with an unnatural amino acid (UAA) at a position corresponding to S6 of SEQ ID NO:
135;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to S40 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to S40 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to S160 of SEQ ID NO:
121;
(xi) the amino acid sequence of SEQ ID NO:
136, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
136;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to T47 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to T47 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to T167 of SEQ ID NO:
121;
(xii) the amino acid sequence of SEQ ID NO:
137, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
137;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to T78 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to T78 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to T198 of SEQ ID NO:
121;
(xiii) the amino acid sequence of SEQ ID NO:
138, with an unnatural amino acid (UAA) at a position corresponding to N6 of SEQ ID NO:
138;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to N84 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to N84 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to N204 of SEQ ID NO:
121;
(xiv) the amino acid sequence of SEQ ID NO:
139, with an unnatural amino acid (UAA) at a position corresponding to V6 of SEQ ID NO:
139;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to V85 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to V85 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to V205 of SEQ ID NO:
121;
(xv) the amino acid sequence of SEQ ID NO:
140, with an unnatural amino acid (UAA) at a position corresponding to N6 of SEQ ID NO:
140;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to N86 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to N86 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to N206 of SEQ ID NO:
121;
(xvi) the amino acid sequence of SEQ ID NO:
141, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
141;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to K93 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to K93 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to K213 of SEQ ID NO:
121;
(xvii) the amino acid sequence of SEQ ID NO:
142, with an unnatural amino acid (UAA) at a position corresponding to D6 of SEQ ID NO:
142;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to D95 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to D95 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to D215 of SEQ ID NO:
121;
(xviii) the amino acid sequence of SEQ ID NO:
143, with an unnatural amino acid (UAA) at a position corresponding to 16 of SEQ ID NO:
143;
the amino acid sequence of SEQ ID NO:
144, with an unnatural amino acid (UAA) at a position corresponding to 123 of SEQ ID NO:
144;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to 1136 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to 1256 of SEQ ID NO:
121;
(xix) the amino acid sequence of SEQ ID NO:
145, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
145;
the amino acid sequence of SEQ ID NO:
144, with an unnatural amino acid (UAA) at a position corresponding to K44 of SEQ ID NO:
144;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to K157 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to K277 of SEQ ID NO:
121;
(xx) the amino acid sequence of SEQ ID NO:
146, with an unnatural amino acid (UAA) at a position corresponding to Y6 of SEQ ID NO:
146;
the amino acid sequence of SEQ ID NO:
144, with an unnatural amino acid (UAA) at a position corresponding to Y48 of SEQ ID NO:
144;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to Y161 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to Y281 of SEQ ID NO:
121;
(xxi) the amino acid sequence of SEQ ID NO:
147, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
147;
the amino acid sequence of SEQ ID NO:
144, with an unnatural amino acid (UAA) at a position corresponding to K58 of SEQ ID NO:
144;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to K171 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to K291 of SEQ ID NO:
121;
(xxii) the amino acid sequence of SEQ ID NO:
148, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
148;
the amino acid sequence of SEQ ID NO:
144, with an unnatural amino acid (UAA) at a position corresponding to K60 of SEQ ID NO:
144;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to K173 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to K293 of SEQ ID NO:
121;
(xxiii) the amino acid sequence of SEQ ID NO:
149, with an unnatural amino acid (UAA) at a position corresponding to N6 of SEQ ID NO:
149;
the amino acid sequence of SEQ ID NO:
144, with an unnatural amino acid (UAA) at a position corresponding to N67 of SEQ ID NO:
144;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to N180 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to N300 of SEQ ID NO:
121;
(xxiv) the amino acid sequence of SEQ ID NO:
150, with an unnatural amino acid (UAA) at a position corresponding to F6 of SEQ ID NO:
150;
the amino acid sequence of SEQ ID NO:
151, with an unnatural amino acid (UAA) at a position corresponding to F64 of SEQ ID NO:
151;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to F287 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to F407 of SEQ ID NO:
121;
and/or
(xxv) the amino acid sequence of SEQ ID NO:
191, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
191;
the amino acid sequence of SEQ ID NO:
129, with an unnatural amino acid (UAA) at a position corresponding to K16 of SEQ ID NO:
129;
the amino acid sequence of SEQ ID NO:
130, with an unnatural amino acid (UAA) at a position corresponding to K16 of SEQ ID NO:
130;
or the amino acid sequence of SEQ ID NO:
121, with an unnatural amino acid (UAA) at a position corresponding to K136 of SEQ ID NO:
121;
and/or
wherein the antibody comprises a light chain, or a fragment thereof, comprising:
(i) the amino acid sequence of SEQ ID NO:
152, with an unnatural amino acid (UAA) at a position corresponding to V6 of SEQ ID NO:
152;
the amino acid sequence of SEQ ID NO:
153, with an unnatural amino acid (UAA) at a position corresponding to V15 of SEQ ID NO:
153;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to V15 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to V15 of SEQ ID NO:
155;
(ii) the amino acid sequence of SEQ ID NO:
156, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
156;
the amino acid sequence of SEQ ID NO:
153, with an unnatural amino acid (UAA) at a position corresponding to T20 of SEQ ID NO:
153;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to T20 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to T20 of SEQ ID NO:
155;
(iii) the amino acid sequence of SEQ ID NO:
157, with an unnatural amino acid (UAA) at a position corresponding to R6 of SEQ ID NO:
157;
the amino acid sequence of SEQ ID NO:
158, with an unnatural amino acid (UAA) at a position corresponding to R1 of SEQ ID NO:
158;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to R24 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to R24 of SEQ ID NO:
155;
(iv) the amino acid sequence of SEQ ID NO:
159, with an unnatural amino acid (UAA) at a position corresponding to S6 of SEQ ID NO:
159;
the amino acid sequence of SEQ ID NO:
160, with an unnatural amino acid (UAA) at a position corresponding to S4 of SEQ ID NO:
160;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to S60 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to S60 of SEQ ID NO:
155;
(v) the amino acid sequence of SEQ ID NO:
161, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
161;
the amino acid sequence of SEQ ID NO:
162, with an unnatural amino acid (UAA) at a position corresponding to K10 of SEQ ID NO:
162;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to K107 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to K107 of SEQ ID NO:
155;
(vi) the amino acid sequence of SEQ ID NO:
163, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
163;
the amino acid sequence of SEQ ID NO:
162, with an unnatural amino acid (UAA) at a position corresponding to T12 of SEQ ID NO:
162;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to T109 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to T109 of SEQ ID NO:
155;
(vii) the amino acid sequence of SEQ ID NO:
164, with an unnatural amino acid (UAA) at a position corresponding to V6 of SEQ ID NO:
164;
the amino acid sequence of SEQ ID NO:
162, with an unnatural amino acid (UAA) at a position corresponding to V13 of SEQ ID NO:
162;
the amino acid sequence of SEQ ID NO:
154, with an unnatural amino acid (UAA) at a position corresponding to V110 of SEQ ID NO:
154;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to V110 of SEQ ID NO:
155;
(viii) the amino acid sequence of SEQ ID NO:
165, with an unnatural amino acid (UAA) at a position corresponding to A6 of SEQ ID NO:
165;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to A1 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to A111 of SEQ ID NO:
155;
(ix) the amino acid sequence of SEQ ID NO:
167, with an unnatural amino acid (UAA) at a position corresponding to Q6 of SEQ ID NO:
167;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to Q37 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to Q147 of SEQ ID NO:
155;
(x) the amino acid sequence of SEQ ID NO:
168, with an unnatural amino acid (UAA) at a position corresponding to L6 of SEQ ID NO:
168;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to L44 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to L154 of SEQ ID NO:
155;
(xi) the amino acid sequence of SEQ ID NO:
169, with an unnatural amino acid (UAA) at a position corresponding to G6 of SEQ ID NO:
169;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to G47 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to G157 of SEQ ID NO:
155;
(xii) the amino acid sequence of SEQ ID NO:
175, with an unnatural amino acid (UAA) at a position corresponding to K6 of SEQ ID NO:
175;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to K59 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to K169 of SEQ ID NO:
155;
(xiii) the amino acid sequence of SEQ ID NO:
170, with an unnatural amino acid (UAA) at a position corresponding to A6 of SEQ ID NO:
170;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to A83 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to A193 of SEQ ID NO:
155;
(xiv) the amino acid sequence of SEQ ID NO:
171, with an unnatural amino acid (UAA) at a position corresponding to V6 of SEQ ID NO:
171;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to V95 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to V205 of SEQ ID NO:
155;
(xv) the amino acid sequence of SEQ ID NO:
172, with an unnatural amino acid (UAA) at a position corresponding to T6 of SEQ ID NO:
172;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to T96 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to T206 of SEQ ID NO:
155;
and/or
(xvi) the amino acid sequence of SEQ ID NO:
173, with an unnatural amino acid (UAA) at a position corresponding to S6 of SEQ ID NO:
173;
the amino acid sequence of SEQ ID NO:
166, with an unnatural amino acid (UAA) at a position corresponding to $98 of SEQ ID NO:
166;
or the amino acid sequence of SEQ ID NO:
155, with an unnatural amino acid (UAA) at a position corresponding to S208 of SEQ ID NO:
155.

467 more elements

Facts

Application

18/044,943Filed 10 Sep 2021

Priority

10 Sep 2020

Published

26 Sep 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 47/6803
Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent: drugs conjugated to an antibody or…
A61K 47/68031
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being an auristatin
A61K 47/68033
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being a maytansine
A61K 47/6853
The antibody targeting a determinant of a tumour cell: carcino-embryonic antigens